Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Feb. 28 to March 4, 2022. […]
Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Feb. 28 to March 4, 2022. This roundup includes the latest research news from journal studies and other trusted sources that is most likely to affect clinical practice.
U.S. Surgeon General Investigates COVID-19 Misinformation
FRIDAY, March 4, 2022 (HealthDay News) — An investigation into health misinformation on COVID-19 has been launched by U.S. Surgeon General Vivek Murthy, M.D.
NFL Drops All COVID-19 Restrictions
FRIDAY, March 4, 2022 (HealthDay News) — The National Football League COVID-19 protocols will be lifted immediately under a deal reached between the league and its players association. The agreement makes the NFL one of the first major sports leagues to take such action, CBS News reported.
Molnupiravir for Nonsevere COVID-19 Added to Living Guideline
FRIDAY, March 4, 2022 (HealthDay News) — Molnupiravir is recommended for patients with nonsevere COVID-19 who are at the highest risk for hospitalization, according to the updated World Health Organization living guideline on drugs for COVID-19, published online March 2 in The BMJ.
Vaccine Effectiveness Lower for Teens With Predominant Omicron
THURSDAY, March 3, 2022 (HealthDay News) — For adolescents, BNT162b2 vaccine effectiveness was lower against COVID-19-associated emergency department and urgent care encounters during omicron predominance, according to research published in the March 1 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Homologous Pfizer-BioNTech Booster Safe for Adolescents
THURSDAY, March 3, 2022 (HealthDay News) — For adolescents aged 12 to 17 years, reactions to homologous Pfizer-BioNTech booster vaccination occur with similar frequency as after receipt of the second vaccine dose, and they are generally mild to moderate in severity, according to research published in the March 1 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
White House Unveils New COVID-19 Response Strategy
THURSDAY, March 3, 2022 (HealthDay News) — Accelerated research into new vaccines that could be ready within 100 days of the emergence of a new variant is one of the key features of a new COVID-19 response strategy released by the White House on Wednesday.
Many Older Adults Still Have Not Received Care Delayed by COVID-19
THURSDAY, March 3, 2022 (HealthDay News) — The pandemic disrupted health care for around 30 percent of older adults, according to the results of the latest University of Michigan National Poll on Healthy Aging.
Subsequent Vaccination Cuts Risk for COVID-19 Reinfection
2005 to 2023 Saw More U.S. Women Never Screened for Cervical Cancer 
4CMenB Vaccine Confers Modest Protection Against Gonorrhea in Teens 
AAP Releases Influenza Vaccine Recommendations for All Children 6 Months and Older 
Most U.S. Adults Unsure Which Vaccines CDC Recommends During Pregnancy .jpg)
Pregnancy Complications Rare for Women Receiving CAR T-Cell Therapy 
Higher Parental Vitamin B12 Tied to Lower Prevalence of Birth Defects 
Adenotonsillectomy Tied to Increase in Respiratory Tract Infections in Children 
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders 
